Close menu




August 4th, 2026 | 07:05 CEST

Takeover Candidates in Focus: Steyr Motors Jumps 20%, RE Royalties Draws Interest, and What About Evotec?

  • royalties
  • dividends
  • Automotive
  • renewableenergy
  • Biotechnology
Photo credits: AI

Shares of Steyr Motors briefly surged 20% last week following takeover speculation involving a US-based drone and robotics specialist. Although the discussions have since been terminated, analysts remain bullish on the Austrian manufacturer of specialized engines. RE Royalties could also emerge as a takeover candidate before the end of the year. Dissatisfied with the company's share price performance, management has initiated a strategic review and is evaluating all available options. Its royalty-based business model could prove particularly attractive to well-capitalized strategic or financial buyers. And what about Evotec? The German biotechnology company has repeatedly been the subject of takeover speculation in recent years, with such rumours often triggering sharp share price gains. We take a look at the current situation and assess whether renewed acquisition interest could be on the horizon.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: EVOTEC SE INH O.N. | DE0005664809 , STEYR MOTORS AG | AT0000A3FW25 , RE ROYALTIES LTD | CA75527Q1081 | TSXV: RE , OTCQX: RROYF

Table of contents:


    RE Royalties: A Takeover in the Coming Months?

    At RE Royalties, investors can speculate on a takeover before the end of the year. Although the stock has already gained about 37% in 2026, management considers this insufficient. Consequently, the company has initiated a formal strategic review process. For several months now, a special committee of the board of directors has been examining various options for increasing the company's value over the long term. In addition to strategic partnerships, co-investments, and optimizing the capital structure, a complete sale of the company is also explicitly mentioned. PricewaterhouseCoopers Corporate Finance has also been retained as a financial advisor. Although RE Royalties emphasizes that this does not necessarily have to result in a transaction, the consideration of a sale is thus more than mere speculation.

    For a potential buyer, the established platform would be particularly attractive. Since its founding, RE Royalties has invested approximately CAD 83 million across 27 transactions in about 135 renewable energy projects. The portfolio includes solar and wind farms, battery storage, hydropower, renewable natural gas, and energy efficiency projects across multiple regions, with more than 80% of the investments located in North America. Through long-term royalties and financing arrangements, the company generates recurring revenue without having to operate the facilities itself. At the same time, the model is scalable: new capital can be invested without a corresponding increase in operating costs. Additionally, approximately 40% of the portfolio comes from repeat clients, which speaks to established relationships with project developers and a sound investment selection process.

    RE Royalties could therefore be of particular strategic interest to infrastructure investors, energy companies, or large asset managers from North America seeking to quickly secure a diversified portfolio in the growing renewable energy market. A financially strong owner could provide the company with more capital for further growth and thereby scale the platform.

    https://youtu.be/5dQvcZkFR7E?si=jx0IeY-Wu7Cfqgm6

    Steyr Motors: Analysts Remain Bullish

    Steyr Motors initially sparked speculation on the stock market by announcing a potential takeover offer from Red Cat Holdings. According to the announcement, the US drone and robotics group had signaled preliminary, non-binding interest in a full takeover. At the same time, Steyr also stated that talks were no longer underway. Nevertheless, the stock jumped from EUR 32 to EUR 41 on Tuesday. Since then, the price has slipped back to EUR 35. What happens next?

    According to NuWays, the withdrawn takeover attempt underscores Steyr Motors' strategic importance in the market for unmanned surface vehicles (USVs). The fact that a US drone and robotics company had considered a full takeover speaks to Steyr Motors' strong position as a hard-to-replace, business-critical supplier. Given Red Cat's high valuation and available liquidity, another takeover bid would be financially feasible in principle. Takeover speculation is therefore likely to continue supporting Steyr Motors' stock.

    In the short term, however, NuWays remains cautious. Although the long-term order backlog stands at more than EUR 300 million, only EUR 37 million of that amount has been budgeted for 2026 so far. New orders for locomotives, the K2 main battle tank, or additional UPS projects have not materialized yet. Following the weak first quarter, this lack of order momentum is increasing uncertainty. NuWays anticipates delays rather than permanently canceled projects, but expects that any potential orders might arrive too late to make a significant contribution to 2026 revenue. Consequently, analysts are lowering their estimates to levels below the company's forecast. Due to operating leverage, the lower revenue is likely to have a disproportionately significant impact on profitability.

    From NuWays' perspective, the investment thesis remains intact for the period after 2026. Opportunities include potential vehicle orders from the Spanish and Austrian defence ministries, further projects with KNDS, and the expansion of USV production at Red Cat. Red Cat's Blue Ops division plans to manufacture more than 1,000 USVs in 2027. Steyr Motors is currently the only named engine supplier for the V7 model. NuWays therefore reaffirms its "Buy" recommendation. The price target is reduced from EUR 60 to EUR 53 due to the weaker performance in 2026.

    Evotec: Acquisition on the Horizon?

    And what about Evotec, the perennial takeover target? The German biotech company has repeatedly been touted as a takeover target in recent years. Such speculation regularly led to sharp jumps in the share price. In the spring of 2024, "Bloomberg" reported that several private equity firms were reviewing the Hamburg-based biotech company and its drug pipeline. Things became particularly concrete in November 2024. Initially, the entry of private equity firm Triton as a new major shareholder sparked takeover speculation. A few days later, the US pharmaceutical company Halozyme even submitted a non-binding offer of EUR 11 per share, or approximately EUR 2 billion. Evotec's stock reacted positively. But then, after about a week, Halozyme withdrew its offer.

    Currently, there is no trace of this takeover speculation. Instead, disillusionment prevails following the latest forecast revision. Evotec now expects revenue of only around EUR 570 to 610 million for 2026. Previously, the company had projected EUR 700 to 780 million. In terms of adjusted EBITDA, the company now anticipates a loss of between EUR 70 and 105 million instead of a profit of between EUR 0 and 40 million. Evotec cites lower contributions from existing and potential new partnerships, as well as delays, as the reasons. As a result, the focus for now is on operational issues, the high loss, and the lack of visibility. This appears to be deterring not only shareholders but also strategic buyers.


    Evotec remains something of a black box, facing a range of operational challenges. This uncertainty appears to be deterring not only shareholders but also potential strategic buyers. By contrast, RE Royalties has established an attractive business model in the renewable energy sector. An acquirer could use the platform as a foundation for further expansion, accelerating growth with additional capital. Steyr Motors, meanwhile, occupies a compelling niche within the defence sector. Management's key challenge is to convert its substantial order backlog into sustainable revenue growth. If the company executes successfully, shareholders may ultimately conclude that remaining independent creates more value than a takeover.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by André Will-Laudien on August 4th, 2026 | 09:10 CEST

    "Buy the Dip" in the Life Sciences Supercycle: Gerresheimer, Vidac Pharma, Novo Nordisk, and Pfizer as Top Performers of the Future

    • Biotechnology
    • Pharma
    • LifeSciences
    • Cancer
    • Innovations
    • Obesity

    Rising healthcare spending, an aging population, and an unprecedented depth of research are propelling the life sciences sector into a multi-year supercycle. And there are some strong players! Gerresheimer stands out as a brilliant infrastructure asset and a leading provider of high-quality primary packaging. In the field of injections and biologics, the company benefits directly from the explosion of complex therapies and GLP-1 markets. Vidac Pharma is conducting research in the field of cancer and leveraging the Warburg effect for its upcoming studies—a classic high-beta play for investors betting on above-average growth. Novo Nordisk remains the undisputed flagship of the obesity and diabetes wave, and Pfizer is using the current lull in valuations as an opportunity to ignite the next phase of growth with a broad pipeline spanning oncology, vaccines, and new forms of therapy. Who belongs in the portfolio for the next life sciences boom?

    Read

    Commented by Fabian Lorenz on August 4th, 2026 | 07:30 CEST

    Alarm at Plug Power! Is Now the Time to Buy thyssenkrupp nucera? dynaCERT Management Remains Optimistic!

    • Hydrogen
    • cleantech
    • Diesel
    • Retrofitting
    • renewableenergy

    While an operational turnaround is taking shape at dynaCERT, its share price has yet to respond. However, analysts maintain a "Buy" recommendation on the cleantech stock and assign a fair value of EUR 0.48. With the shares currently trading at around EUR 0.065, they see significant upside potential. The company's German management team also recently expressed confidence in the business outlook. Meanwhile, thyssenkrupp nucera delivered results that were less disappointing than many had expected. The question now is whether that will be enough to reignite momentum for Germany's hydrogen hopeful. Plug Power, on the other hand, sought to reassure investors with a recent press release. Instead, the announcement appears to have intensified concerns. The stock continues its downward trend, as liquidity may not be sufficient and a capital increase is expected.

    Read

    Commented by Matthias Schomber on August 3rd, 2026 | 07:45 CEST

    Alarm at Volkswagen, Steyr Motors Takeover Called Off! When Will dynaCERT Spark a Long-Awaited Breakout?

    • cleantech
    • Hydrogen
    • greenhydrogen
    • Diesel
    • Automotive
    • Electromobility

    While some of Germany's largest automakers are grappling with a deepening crisis and planning historic restructuring measures, other well-known companies are also facing major challenges. Volkswagen is struggling with a sharp decline in vehicle sales and sweeping cost-cutting plans that have unsettled investors, a trend reflected in the company's weakening share price. At the same time, Austrian engine specialist Steyr Motors is navigating a highly challenging market environment and is being forced to redefine its strategic direction. Most recently, the company put an end to takeover speculation after acquisition talks failed to result in a transaction. Amid these turbulent times, investors are turning their attention to smaller players, such as the Canadian cleantech company dynaCERT. The company has developed an innovative technology for internal combustion engines designed to reduce fuel consumption and emissions, potentially delivering meaningful cost savings for fleet operators.

    Read